Long-term Tolerability and Efficacy of Degarelix: 5-Year Results From a Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix
Author:
Crawford E. David,
Shore Neal D.ORCID,
Moul Judd W.ORCID,
Tombal Bertrand,
Schröder Fritz H.,
Miller Kurt,
Boccon-Gibod Laurent,
Malmberg Anders,
Olesen Tine Kold,
Persson Bo-Eric,
Klotz Laurence
Reference21 articles.
1. Degarelix acetate for the treatment of prostate cancer;Klotz;Drugs Today (Barc),2009
2. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer;Klotz;BJU Int,2008
3. Testosterone surge: rationale for gonadotropin-releasing hormone blockers?;van Poppel;Urology,2008
4. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics;Tombal;Eur Urol,2010
5. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study;Schroder;BJU Int,2010
Cited by
49 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献